Background-A number of phosphorus ( 31 P) magnetic resonance spectroscopy (MRS) studies link alterations of high-energy phosphate metabolism in valvular disease and cardiomyopathy to the clinical severity of heart failure. However, correlations between MRS and indexes of ventricular dysfunction are inconclusive to date. We examined whether changes in 31 P MRS are associated with the impaired contractility, which predisposes to chronic congestive heart failure in patients with mitral regurgitation. Methods and Results-Thirteen normal control subjects and 22 patients with echocardiographically characterized chronic mitral regurgitation were studied by 31 P MRS. The apical phosphocreatine-to-ATP ratio (PCr/ATP) was lower in severe disease (PϽ.02) and those on therapy (nϭ13, 1.29Ϯ0.29, PϽ.01) in contrast to control subjects (nϭ13, 1.61Ϯ0.3). Compared to those with mild mitral regurgitation, patients with more severe incompetence had lower mean myocardial PCr/ATP ratios (mild, nϭ6, 
T he mechanisms underlying deterioration of myocardial contractility in conditions such as MR (mitral incompetence) are poorly understood. Abnormal high-energy phosphorus and other metabolism appears to play a role, 1,2 and several recent reports using 31 P MRS [3] [4] [5] [6] describe altered PCr/ATP among patients with aortic valve disease, 7, 8 cardiomyopathy, 9 ,10 ischemia, [11] [12] [13] and other disorders affecting the LV (for reviews, see References 14 through 16).
One observation, the reduced PCr/ATP of the hypertrophied failing myocardium, 7, 8 has focused attention on structural changes in the ventricle that may be relevant to the biochemical changes.
To explore this, we studied MR, a valvular disorder characterized by a range of abnormalities in contractility, eccentric hypertrophy, and severity of dilated cardiomyopathy, and we examined for links between symptoms of heart failure, echocardiographic abnormalities, and changes in PCr/ATP.
Methods Subjects
Twenty-two patients (age range, 17 to 78 years; meanϮSD, 54.6Ϯ17 years; height, 173Ϯ11 cm; weight, 66.4Ϯ12.9 kg; BSA, 1.76Ϯ0.2 m 2 ; 17 men, 5 women) with MR were compared with 13 age-and sex-matched normal control subjects. To limit the effects of confounding factors, all patients fulfilled the following criteria: (1) they had clinically stable MR for at least 3 months, (2) they were able to tolerate lying prone, (3) they were in sinus rhythm (nϭ16) or well-controlled atrial fibrillation (nϭ6) and did not suffer from lung disease, pulmonary or systemic hypertension, acute or healed myocardial infarction, angina pectoris, significant aortic valve disease, or LV dilatation caused by idiopathic, myocarditic, or ischemic cardiomyopathy. Disease severity was characterized from the degree of dyspnea (NYHA classes I through IV) at the time of the MRS study. Patients were recruited and studied randomly as they presented within a month of referral or soon after annual outpatient review. Patients with mild incompetence had been referred with palpitations or a clinically detected mitral murmur.
The symptomatic status and echocardiographic severity of the patients with MR are listed in Table 1 .
Patients were fully informed about the study, permission for which was provided by the Central Oxford Regional Ethics Committee.
Echocardiography
The degree of mitral valve leakage was determined from the color-flow jet on Doppler echocardiography (mild, Ͻ4.0 cm 2 ; severe, Ͼ8.0 cm 2 ) 17 with a Hewlett-Packard Sonos 1000, 2.5/2.0-MHz phased-array transducer, narrow-sector angle for color flow (30°). The hearts were further characterized by measuring ESD, EDD, LA dimensions, and Th (all in centimeters) ( Table 2 ). The EDD and Th measurements were recorded with the echo beam directed at the LV just caudal to the mitral leaflet tips and angled so that the septum and posterior wall endocardium lay perpendicular to the beam (left parasternal long-axis view). Derived measurements such as FS% (FS%ϭ(EDDϪESD)/EDD), LVM in grams 18 adjusted for BSA, and LV meridional wall stress in grams per square centimeter based on cuff sphygmomanometry 19 -21 were calculated. The mean of three measurements was used for final analysis (the mean for atrial fibrillation patients was derived from six ventricular contractions). Tables 2, 3 , and 4 summarize the measured and derived echocardiographic parameters and show the differences among mild, moderate, and severe cases of incompetence with respect to the ESD, EDD, Th, LA, LVM/BSA and FS%. The echocardiographic characteristics of dyspneic patients and those on treatment for heart failure are also listed (Table 4) , and the intercorrelations between the echocardiographic measurements are tabulated in Table 5 .
P MRS
Seventeen patients and 8 control subjects were studied successfully with 1D CSI 22 in a 2-T magnet (Oxford Instruments). Five patients and 5 control subjects underwent examination with a comparable 1D technique, PMRFI 4 in a 1.9-T magnet equipped with the same Biospec NMR spectrometer (Oxford Research Systems). Acquisition and analysis of data were unsuccessful in 1 patient with severe MR and 3 control subjects.
Patients were positioned prone on 6.5-cm-diameter 31 P MRS receiver coils, and an ECG was attached. 23 Coil location relative to the apex and free wall of the LV was optimized before MRS acquisitions by prone echocardiography and also by MRI in the CSI studies.
The 1D CSI spectroscopy was performed using a surface coil consisting of a balanced three-turn 6.5-cm-diameter 31 P receiver coil and a 0.4ϫ0.4-m transmit coil. 22 A 0.4ϫ0.4-m 1 H transmit coil and an 8ϫ13-cm figure-eight 1 H receiver coil were used for MRI and for shimming the magnet to optimize the field homogeneity for the 31 P MRS study by use of an unlocalized water spectrum. Scout ECGgated MRI was performed with a spin-echo sequence (TE, 34 ms; NEX, 2; acquisition delay, 0.15 seconds after the R wave), giving 2.5-mm-per-pixel resolution from 1.0-cm-thick slices. After MRI and shimming, cardiac-gated 31 P MRS was performed with excitation pulses adjusted to optimize the PCr signal in an unlocalized eight-scan spectrum.
11,24 A 64-step 1D CSI 31 P data set was then collected at the heart rate in Ϸ12 minutes with 1.0-cm resolution as a function of depth through the chest wall and heart. After the 1D CSI acquisition, two unlocalized cardiac-gated spectra were recorded to determine saturation correction factors for PCr/ATP. One spectrum (NEX, 100) was acquired at the heart rate as in the CSI study, and the other (NEX, 16 scans) was acquired with a 15-second repetition delay. PMRFI 31 P MRS studies were carried out with a double-concentric surface coil (transmitter diameter, 15 cm; receiver diameter, 6.5 cm) from cylindrical sections calibrated from experiments on multicompartment samples. 25 A phantom of diphenylphosphate located at the center of the coil served as a reference marker. Acquisitions were cardiac-gated at twice the cardiac period (TR, Ϸ2 seconds). Scout MRI was performed with a figure-eight 20ϫ20-cm surface coil.
Cardiac spectra were identified from both MRI ( Figure 1 ) and depth profiles. The latter plot (Figure 3 ) reveals the prominent PCr and higher PCr/ATP in the chest wall and demonstrates the transition to the lower ratios characteristic of the myocardium. 3, 4, 7, 26 Spectral analysis: PMRFI and 1D CSI spectra were quantified by measuring peak areas by triangulation and by automated curve fitting in the frequency domain with standard Bruker Instrument integration software. Metabolite ratios were cross-checked blindly by two independent investigators. All PCr/ATP calculations were based on the gamma ATP resonance 4, 8 because of off-resonance effects on the ␤ATP peak in some patients.
Myocardial PCr/ATP from CSI data sets was corrected for partial saturation by use of the correction factors calculated from PCr/ATP measured in the unlocalized spectra acquired at the heart rate and at 15 seconds. 24 Examples of such spectra are shown in Figure 2 . The saturation correction factors were similar for each subject, so the mean was used for correction in eight CSI studies in which the individual saturation factors had not been measured. 24, 27 PMRFI data were similarly adjusted by use of the known flip angle and heart rate of the individual patients and the spin-lattice relaxation times (T1). 28 Adjustment for blood contamination was performed by reducing the size of the ATP by an amount equal to one sixth of the area of the combined peaks representing 2,3 DPG 7-9 when this peak was prominent. In practice, the correction was applied when (1) the area
Selected Abbreviations and Acronyms
1D CSI ϭ one-dimensional chemical shift imaging 2,3 DPG ϭ 2,3 diphosphoglycerate BSA ϭ body surface area EDD ϭ end-diastolic diameter ESD ϭ end-systolic diameter FS% ϭ percent fractional shortening LA ϭ left atrial dimension LV ϭ left ventricular/left ventricle LVM ϭ LV mass MR ϭ mitral regurgitation MRS ϭ magnetic resonance spectroscopy MVR ϭ mitral valve replacement NEX ϭ number of averaged experiments PCr/ATP ϭ phosphocreatine-to-ATP ratio PMRFI ϭ phase-modulated rotating frame imaging TE ϭ echo time Th ϭ LV thickness TR ϭ repetition time 
CHF indicates congestive heart failure. *One man died postoperatively owing to LV dysfunction.
of the signal from combined 2,3 DPG resonances (at 5.3 and 6.2 ppm) was equal to or greater than that of the ␥ATP and (2) the amplitude of the 3 phosphoglycerate was equal to or lower than that of the 2 phosphoglycerate. 29 Such corrections were applied to cardiac spectra from five normal control subjects and five patients with MR (moderateϭ1; severeϭ4). (This suggests that the presence of prominent blood signals is not a particular feature of dilated cardiomyopathy and is likely to reflect the depth and position of the sampling volume in a proportion of both the control subjects and valvular heart disease patients.) Data are presented as meanϮSD and compared by use of both the basic Student unpaired t test and the Welch modified two-sample t test. The comparison of PCr/ATP with the grade of mitral incompetence was examined with ANOVA. Normal distribution of the data was checked with the Kolmogorov Smirnov test. The nonparametric Spearman test was applied when the data were not normally distributed, eg, wall stress. Simple correlations were examined, and values of PϽ.05 and r 2 Ͼ.45 were accepted as significant and as evidence favoring a relationship. There were no significant differences in myocardial PCr/ATP measured by CSI and PMRFI either before or after saturation and blood correction (uncorrected control subjects: CSI, nϭ8, 1.66Ϯ0.38 versus PMRFI, nϭ5, 1.52Ϯ0.14). The individual ratios for patients are tabulated in Table  2 (from which the correction factors can be derived), and both the uncorrected and saturation corrected mean values are presented in Tables 3 and 4 .
Results

Steady-State High-Energy Phosphorus Metabolism in Mitral Incompetence
Representative 1D CSI spectra from a control and patients with normal and reduced PCr/ATP are illustrated in Figure 3 . A midplateau PMRFI heart spectrum of one patient with severe MR is also shown. The amplitude and area of PCr relative to ATP are highest in the normal and mild MR spectra. To determine whether myocardial high-energy phos- phate metabolism is altered by and correlated with disease severity in mitral incompetence, we compared PCr/ATP in MR with data from control subjects and measurements from patients categorized according to the severity of incompetence, simple and derived echocardiographic parameters, and symptomatic status.
PCr/ATP: MR Compared With Control Subjects
Some previous reports suggest that LV metabolism may be different among MR patients compared with control subjects. 30, 31 Within the current study group, patients with severe regurgitation (nϭ11, 1.29Ϯ0.3, PϽ.02), dyspneic subjects (nϭ10, 1.21Ϯ0.24, PϽ.003), and those on therapy for heart failure (nϭ13, 1.29Ϯ0.29, PϽ.01) had significantly lower ratios compared with control subjects (nϭ13, 1.61Ϯ0.3). However, the control ratio was not significantly different from the ratio in patients classified echocardiographically with mild or moderate disease, among patients without dyspnea, or in those who did not require treatment for heart failure. These data are presented in Tables 3 and 4 .
PCr/ATP: Mild Versus Moderate Versus Severe MR
The severity of incompetence may determine the extent to which metabolism becomes deranged over time. Compared with the ratio in patients with mild MR (1.73Ϯ0. 17 
PCr/ATP Versus Measured Echocardiographic Parameters
To explore possible structural or functional correlates of the above finding, the relationship between individual PCr/ATP and standard echocardiographic indexes of LA, LV dimensions, and LV Th was examined. Figure 4 
PCr/ATP Versus Derived Echocardiographic Measurements
Correlation was found between the metabolic ratio and both the LVM/BSA (r 2 ϭ.52, PϽ.0001) and FS% (r 2 ϭ.5, PϽ.001), but the measured wall stress was not related to PCr/ATP (r 2 ϭ.14, PϭNS) even when tested with the nonparametric Spearman test (Table 5) . . PCr/ATP of subjects treated both medically and referred for MVR within 2 months was lower than that of those on medical therapy alone, but the difference did not achieve conventional statistical significance (1.17Ϯ0.23, nϭ8 versus 1.48Ϯ0.29, nϭ5; Table 4 ).
Discussion
In the current study, intracellular myocardial biochemistry of the LV free wall and apex of the heart with mitral incompetence was examined by use of an index based on measurements of phosphate atomic nuclei in PCr and ATP. The findings show that patients have normal PCr/ATP when MR is mild but develop reduced PCr/ATP with severe disease, indicative of a reduced potential for maintaining the ATP supply for muscular contraction. Patients with symptoms of heart failure and those receiving antifailure therapy also exhibited lower PCr/ATP compared with the asymptomatic and untreated groups. The latter observations are consistent with previous studies of steady state high-energy phosphorus metabolism in valvular heart disease 7,32 and heart failure caused by cardiomyopathy. 8, 9 The clearest correlation between a simple echocardiographic measurement and the biochemical index is PCr/ATP versus ESD. Patients whose LVs are larger than normal at end systole have decreased PCr compared with ATP concentrations, and the greater the dilatation, the lower the ratio. This finding is consistent with the significant correlation between PCr/ATP and FS%. Such observations suggest that the prevailing PCr/ATP may be linked to factors determining the efficiency of contractility. Hence, it represents a potential biochemical marker of LV function.
The biochemical index also links LV growth to the changes in PCr/ATP. Mass is derived using cubed EDD and LV myocardial thickness 18 and is subject not only to the variability in these measurements but also to patient size and the effects of conditions that increase wall thickness such as hypertension. The measurements presented were adjusted for BSA, and confounding conditions were excluded during patient recruitment, thereby supporting the proposal that increased LVM is associated with an altered PCr/ATP, as has been shown with animal models. [33] [34] [35] Correlation of derived echocardiographic measurements such as FS% and LVM/BSA with PCr/ATP reflects the relationship with the measured echocardiographic parameters from which these are calculated. Our data show no correlation between the biochemical ratio and the calculated wall stress. 20 The altered PCr/ATP reflects altered homeostasis of highenergy phosphorus metabolism in MR. The abnormality results perhaps from one or more of the many biochemical mechanisms that maintain efficient cellular contractility. 1 H MRI of the heart and chest wall. A spectrum from the inner row of the free wall and apex of the heart (section 5) using the Glinfit integration program is also shown. RV indicates right ventricle; Sep, septum; Adipose, adipose tissue; and Pi, inorganic phosphate.
Figure 2.
Relaxed and fully saturated spectra of the combined chest wall and heart from a patient with valvular incompetence.
Recently, Massie et al 35 showed that the proportion of glucose that the heart oxidizes is higher in pigs with LV hypertrophy. They argued that a different substrate preference could offer a partial explanation for the lower PCr/ATP in LV hypertrophy because a low ratio has been observed when glucose is the sole substrate in perfused hearts. 36 However, as they pointed out, the relevance of their finding to humans in whom a mixture of substrates is available remains uncertain. Reduction of PCr/ATP may be determined by chronic myocardial hypoperfusion, but it is unlikely that decreased PCr/ATP and impaired systolic function among patients with chronic stable regurgitation is analogous to the PCr depletion that occurs during global myocardial ischemia in the isolated heart preparation. 34 In contrast, intracellular biochemical changes associated with concentric hypertrophy may depend more on perfusion to the endocardium (especially rate related). 33, 37, 38 Altered biochemistry is reported by other investigators who studied patients with mitral valve prolapse. The arterial and coronary sinus blood lactate levels were increased 30 in a group with mitral valve prolapse, and right ventricular endomyocardial biopsies 31 demonstrated evidence of mitochondrial degeneration. However, some investigators (eg, Chidsey et al 39 ) have reported normal high-energy phosphorus metabolism in the papillary muscle of patients with MR compared with myocardial tissue from congenital heart disease patients.
Our findings demonstrate that deteriorating myocardial function in mitral incompetence is associated with altered PCr/ATP. The mechanism of this may be inefficient creatine phosphorylation by creatine kinase 40, 41 and decreased intracellular creatine. 2 Because creatine uptake into muscle occurs through specific sodium-dependent membrane transport that requires energy, 42 this process may be particularly susceptible to abnormal myocardial energy demand and may represent an adaptive change.
The present metabolic findings are relevant not only to the understanding of myocardial metabolism but also to the possible role of 31 P MRS as a technique for investigating and clinically managing patients with valvular heart disease. We have previously proposed that serial noninvasive biochemical monitoring represents a potentially important investigation for improving management decisions relating to valve surgery. 7 This applies particularly to MR, a condition in which the optimal timing of MVR is often difficult to choose. Our study identified a close relationship between 31 P MRS measurements and systolic function. The latter, as measured by echocardiography, determines morbidity and mortality both with and without surgery. [43] [44] [45] The link between systolic function and PCr/ATP presents a further biochemical marker for these epidemiological observations. In support of the observations, low PCr/ATP has been found to be associated with increased mortality in patients with dilated cardiomyopathy. 46 The current measurements were made at 1.9 to 2.0 T with two currently accepted techniques from patients who were carefully chosen on the basis of clinical criteria and from whom metabolic measurements could be made with good 31 P MRS signal-to-noise ratios. Standard corrections were applied, and data adjustment for partial saturation and blood contamina- tion was performed. High magnetic field strengths of Ն4 T offer further potential for increasing the sensitivity 47 and scope 48 of such studies. MR was assessed here with echocardiography but ultimately could be evaluated during combined conventional/ tagging 49 MRI and MRS examination. In conclusion, 31 P MRS demonstrates altered PCr/ATP in patients with MR. Lower PCr/ATP ratios are linked to echocardiographic indexes of severity, including systolic function and eccentric hypertrophy, and to symptoms of heart failure. The findings may reflect altered creatine homeostasis and may be helpful in the management of patients awaiting MVR.
